BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giulino LB, Bussel JB, Neufeld EJ; Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr. 2007;150:338-344, 344.e1. [PMID: 17382107 DOI: 10.1016/j.jpeds.2006.12.038] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Schäppi MG, Ozsahin H, Peyrard T, Gumy-pause F, Posfay-barbe KM, Chardot C, Belli DC, Siegenthaler MA. Severe autoimmune hemolytic anemia in a liver transplanted child. Pediatric Transplantation 2008;12:809-12. [DOI: 10.1111/j.1399-3046.2008.00934.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
2 Nageswara Rao AA, Arteaga GM, Reed AM, Gloor JM, Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009;52:536-8. [PMID: 19061212 DOI: 10.1002/pbc.21878] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
3 Belot A, Cochat P. [Biological therapy in pediatrics]. Arch Pediatr 2010;17:1573-82. [PMID: 20880681 DOI: 10.1016/j.arcped.2010.08.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Oh S, Cudrici C, Ito T, Rus H. B-cells and humoral immunity in multiple sclerosis. Implications for therapy. Immunol Res 2008;40:224-34. [PMID: 17960498 DOI: 10.1007/s12026-007-8009-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
5 Schulze J, Bader P, Henke U, Rose MA, Zielen S. Severe Bullous Pemphigoid in an Infant- Successful Treatment with Rituximab. Pediatric Dermatology 2008;25:462-5. [DOI: 10.1111/j.1525-1470.2008.00751.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
6 Gallego S, Llort A, Gros L, Sanchez de Toledo Jr J, Bueno J, Moreno A, Nieto J, Sanchez de Toledo J. Post-transplant lymphoproliferative disorders in children: The role of chemotherapy in the era of rituximab. Pediatric Transplantation 2010;14:61-6. [DOI: 10.1111/j.1399-3046.2009.01181.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
7 De Braganca KC, Packer RJ. Neurotoxicity of chemotherapeutic and biologic agents in children with cancer. Curr Neurol Neurosci Rep 2008;8:114-22. [DOI: 10.1007/s11910-008-0019-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Yu X, Marshall MJE, Cragg MS, Crispin M. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. BioDrugs 2017;31:151-66. [DOI: 10.1007/s40259-017-0223-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
9 Walsh M, Jayne D. Targeting the B cell in vasculitis. Pediatr Nephrol 2009;24:1267-75. [DOI: 10.1007/s00467-008-1010-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2009;52:847-52. [PMID: 19214977 DOI: 10.1002/pbc.21965] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
11 Jansson AF, Sengler C, Kuemmerle-deschner J, Gruhn B, Kranz AB, Lehmann H, Kleinert D, Pape L, Girschick HJ, Foeldvari I, Haffner D, Haas JP, Moebius D, Foell D, Peitz J, Grote V. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 2011;30:87-97. [DOI: 10.1007/s10067-010-1630-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
12 Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C. Rituximab Therapy to Prevent Relapse in Chronic Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Child. Pediatric Hematology and Oncology 2011;28:167-72. [DOI: 10.3109/08880011003739414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
13 Svahn J, Fioredda F, Calvillo M, Molinari AC, Micalizzi C, Banov L, Schmidt M, Caprino D, Marinelli D, Gallisai D, Dufour C. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. British Journal of Haematology 2009;145:96-100. [DOI: 10.1111/j.1365-2141.2009.07594.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
14 Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008;28 Suppl 1:S42-5. [PMID: 18322785 DOI: 10.1007/s10875-008-9182-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 71] [Article Influence: 7.3] [Reference Citation Analysis]
15 Haller W, Hind J, Height S, Mitry R, Dhawan A. Successful treatment of mixed-type autoimmune hemolytic anemia with rituximab in a child following liver transplantation. Pediatric Transplantation 2010;14:E20-5. [DOI: 10.1111/j.1399-3046.2009.01128.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ahmad N, Zaidi A, Badar F, Maaz A, Akram MS. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia-Pacific Journal of Clinical Oncology 2010;6:49-56. [DOI: 10.1111/j.1743-7563.2009.01264.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Griepentrog GJ, Vickers RW, Karesh JW, Azari AA, Albert DM, Bukat CN. A clinicopathologic case study of two patients with pediatric orbital IgG4-related disease. Orbit 2013;32:389-91. [PMID: 23957841 DOI: 10.3109/01676830.2013.822899] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
18 Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Current Opinion in Pediatrics 2008;20:17-22. [DOI: 10.1097/mop.0b013e3282f424b0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
19 Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149-69. [DOI: 10.1111/j.1365-2141.2008.07054.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 105] [Article Influence: 11.7] [Reference Citation Analysis]
20 Paling A, Stefan DC. Idiopathic thrombocytopenic purpura in childhood: a 10-year audit. Hematology 2013;13:175-80. [DOI: 10.1179/102453308x316167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
21 Lima XT, Seidler EM, Lima HC, Kimball AB. Long-term safety of biologics in dermatology. Dermatologic Therapy 2009;22:2-21. [DOI: 10.1111/j.1529-8019.2008.01212.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
22 Akbayram S, Doğan M, Akgün C, Erbey F, Çaksen H, Öner AF. Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Targ Oncol 2010;5:291-4. [DOI: 10.1007/s11523-010-0161-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
23 Borker A, Choudhary N. Rituximab. Indian Pediatr 2011;48. [DOI: 10.1007/s13312-011-0098-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 Matsubara K, Takahashi Y, Hayakawa A, Tanaka F, Nakadate H, Sakai M, Maeda N, Oka T, Ishii E, Bessho F, Morimoto T, Goto H, Hashii Y, Hatakeyama N, Shirahata A, Imaizumi M. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol 2014;99:429-36. [PMID: 24609717 DOI: 10.1007/s12185-014-1541-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
25 Azapağasi E, Uysal Yazici M, Eroğlu N, Albayrak M, Kucur Ö, Fettah A. Successful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl. J Pediatr Hematol Oncol 2021;43:e587-91. [PMID: 33306607 DOI: 10.1097/MPH.0000000000002026] [Reference Citation Analysis]
26 Pranzatelli MR, Tate ED, Verhulst SJ, Bertolone SJ, Bhatla D, Granger M, Lebowizc J, Lockhart SK, Wiley JM. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2010;32:e167-72. [PMID: 20606544 DOI: 10.1097/MPH.0b013e3181cf0726] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
27 Miao CH. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 2010;3:469-83. [PMID: 20976115 DOI: 10.1586/ehm.10.33] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
28 Pranzatelli MR, Tate ED, Swan JA, Travelstead AL, Colliver JA, Verhulst SJ, Crosley CJ, Graf WD, Joseph SA, Kelfer HM, Raju GP. B cell depletion therapy for new-onset opsoclonus-myoclonus: Rituximab in OMS. Mov Disord 2010;25:238-42. [DOI: 10.1002/mds.22941] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
29 Harambat J, Lamireau D, Delmas Y, Ryman A, Llanas B, Brissaud O. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review: . Pediatric Critical Care Medicine 2011;12:e90-3. [DOI: 10.1097/pcc.0b013e3181e89f8f] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
30 Jarasvaraparn C, Imran H, Siddiqui A, Wilson F, Gremse DA. Association of autoimmune hepatitis type 1 in a child with Evans syndrome. World J Hepatol 2017;9:1008-12. [PMID: 28878866 DOI: 10.4254/wjh.v9.i23.1008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Cooper N, Bussel JB. The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia. Curr Rheumatol Rep 2010;12:94-100. [DOI: 10.1007/s11926-010-0090-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
32 Gupta N, Sharma S, Seth T, Mishra P, Mahapatra M, Kumar S, Kapoor R, Agarwal N. Rituximab in Steroid Refractory Autoimmune Hemolytic Anemia. Indian J Pediatr 2012;79:803-5. [DOI: 10.1007/s12098-011-0544-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]